Glioma is the most prevalent brain tumor with high mortality and morbidity and the prognosis of patients remain very poor. Glioma therapy is largely limited by the extraordinary invasive capability in glioma and the clinical prognostic biomarker of LGG and GBM remain lacking. So it is urgent and important for us to identify a valuable biomarker to treat glioma patients. SCAMP4 (Secretory Carrier-Associated Membrane Protein 4) has not been reported to be linked to cancer prognostic or any treatments.
We analyze the role of SCAMP4 in LGG and GBM via the publicly available CGGA (The Chinese Glioma Atlas) and TCGA (The Cancer Genome Atlas) database. The correlations between SCAMP4 and the immune cells were analyzed by applying CIBERSORT and TIMER, while R was utilized in the analysis of the statistical data.
Our results indicated that SCAMP4 which is correlated to age, stage, grade and tumor status may be a promising independent prognostic factor in LGG and GBM. Meanwhile, the expression of SCAMP4 is closely associated with some tumor-infiltrating immune cells such as Monocytes, NK cells activated, Macrophages, Mast cells resting and so on. Furthermore, during the in-depth analysis of the integrated correlations, we also find that isocitrate dehydrogenase 1 (IDH1) and SCAMP4 shared similar prognostic values.
Together with all these findings, the identification of SCAMP4 as a new biomarker could elucidate how the immune microenvironment influence the glioma development. With further analysis, SCAMP4 may be a predictor for glioma prognosis.

Copyright © 2021 Elsevier Ltd. All rights reserved.